Beumer H M
Int J Clin Pharmacol Ther Toxicol. 1983 Mar;21(3):147-66.
In a multiple-dose, double-blind parallel group study two groups of 19 male outpatients each with chronic pulmonary obstructive disease received either pirbuterol aerosol (0.4 mg) or orciprenaline aerosol (1.3 mg) 3--4 times daily for 12 weeks (after about 1 week of placebo administration). Bronchodilator efficacy persisted throughout the treatment period. However, the initial (week 0) response to pirbuterol, but not orciprenaline, tended to be greater than responses on subsequent test days. Side effects, changes in blood pressure or pulse rate, and clinical chemical abnormalities were of minor clinical importance, but post-inhalation dysrhythmias were seen in four patients receiving orciprenaline. In both treatment groups, some patients showed prolongation in bleeding and/or clotting times.
在一项多剂量、双盲平行组研究中，两组各有19名患有慢性阻塞性肺病的男性门诊患者，在给予安慰剂约1周后，每天3至4次接受吡布特罗气雾剂（0.4毫克）或奥西那林气雾剂（1.3毫克）治疗，为期12周。在整个治疗期间，支气管扩张剂疗效持续存在。然而，吡布特罗的初始（第0周）反应往往大于随后测试日的反应，而奥西那林则不然。副作用、血压或脉搏率变化以及临床化学异常的临床重要性较小，但在接受奥西那林治疗的4名患者中出现了吸入后心律失常。在两个治疗组中，一些患者的出血和/或凝血时间延长。
